Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology. ALN1003 is a preclinical, non-incretin, oral candidate targeting metabolic dysfunction beyond weight loss that may address insulin resistance, adipose signaling, liver biology, and body composition. ALN1003 is a preclinical, oral, non-hormonal metabolic therapeutic candidate being evaluated for: obesity-related metabolic dysfunction, MASH-relevant biology, and insulin resistance. The firm is advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. The firm is developing ActRII-Fc ligand traps and complementary biologics. The firm's programs include VLR199, VLR247, VLR258, VLR360 and others.